EU 2022/2340 EGCG: Annex III Labels & Dossier Guide
The B2B compliance brief for EU importers sourcing green tea extract under the 800 mg EGCG
A European supplement brand receives a purchase inquiry from a major German health food retailer. The compliance team requests three things before listing: (1) the precise EGCG content per serving in milligrams, confirmed by batch-specific HPLC; (2) proof that daily serving accumulation across all product units cannot exceed 800 mg EGCG; (3) confirmation that all four mandatory label warnings from EU Regulation 2022/2340 appear verbatim in the correct languages.
The brand turns to their Chinese EGCG supplier — who has never heard of Regulation (EU) 2022/2340 and cannot provide EGCG-per-batch documentation in the format required. The brand misses the listing deadline. The product sits in a warehouse while legal counsel reviews the compliance gap.
This scenario repeats daily across EU supplement procurement. Regulation (EU) 2022/2340, in force since 20 December 2022 with full enforcement from 21 June 2023, is directly applicable EU law governing every green tea extract product placed on the EU market containing EGCG. This guide covers the regulatory architecture, verbatim mandatory warning texts, serving size calculation methodology, batch-to-batch variance tolerances, and the complete dossier specification for EU-compliant EGCG procurement.
Daily limit: Green tea extract products sold in the EU must contain less than 800 mg of (−)-epigallocatechin-3-gallate (EGCG) per daily portion. Products delivering ≥800 mg EGCG/day are prohibited under Part B of Annex III to Regulation (EC) No 1925/2006 as amended by Regulation (EU) 2022/2340.
Four mandatory label warnings (verbatim, English): (1) "Should not be consumed if you are consuming other products containing green tea on the same day." (2) "Should not be consumed by pregnant or lactating women and children below 18 years old." (3) "Should not be consumed on an empty stomach." (4) The label must provide the maximum number of daily portions and a warning not to consume 800 mg EGCG or more per day. The label must indicate EGCG content per portion in milligrams.
Novel food exception: Highly purified EGCG containing ≥90% (−)-epigallocatechin-3-gallate is exempt from Regulation 2022/2340 and governed instead by Regulation (EU) 2015/2283 (novel food) and Commission Implementing Regulation (EU) 2017/2470.
Part C scrutiny: All green tea extracts containing EGCG — at any dosage — are simultaneously listed in Part C. The Commission must decide by approximately December 2026 whether to escalate to Part A (prohibited) or retain/modify the Part B restriction.
B2B dossier requirement: EU importers must obtain from their EGCG supplier: batch-specific HPLC EGCG assay; declared EGCG content per kilogram of ingredient; batch-to-batch variance data (target ≤5% RSD); and a signed quality agreement confirming specification adherence.
- Regulatory Architecture: EC 1925/2006 Annex III and How 2022/2340 Fits In
- Part B vs. Part C: What Each Classification Means for Your Product
- The Four Mandatory Warning Texts — Verbatim, Legally Required
- Technical Parameter Table: Daily Limits, Label Requirements, and Scope
- Serving Size Calculation: Staying Below 800 mg with Batch Variance Safety Margin
- EFSA Science Behind the Limit: Hepatotoxicity, Transaminases, and the 800 mg Basis
- The Novel Food Exception: EGCG ≥90% Under Regulation 2017/2470
- Supplier Audit Checklist: Batch Consistency and Dossier Requirements
- Blue Eyes Biotech Solution: EU-Compliant EGCG with Standardized Dossiers
- FAQ
1. Regulatory Architecture: EC 1925/2006 Annex III and How Regulation 2022/2340 Fits In
Regulation (EC) No 1925/2006 on the addition of vitamins, minerals, and certain other substances to foods provides the EU's legislative framework for controlling substances added to food or used in food manufacture. Annex III contains three lists: Part A — Prohibited substances; Part B — Restricted substances (permitted only under specified conditions — violations = placing prohibited product on market); Part C — Substances under Community scrutiny (under evaluation; monitoring and possible future action).
Commission Regulation (EU) 2022/2340, published in the Official Journal on 1 December 2022 (L 310, pp. 7–10), added green tea extracts containing EGCG to both Part B and Part C simultaneously. Part B imposes immediate enforceable use conditions (<800 mg/day limit and four mandatory label warnings); Part C flags the substance for further EFSA safety review with a Commission decision deadline approximately December 2026. The final decision could result in Part A (full prohibition) or modification of Part B conditions.
Entry into force: 20 December 2022 (20 days after OJ publication).
Full enforcement: 21 June 2023 — products placed on market before 20 December 2022 had a sell-through period until this date. As of 21 June 2023, every EU-market green tea extract containing EGCG must comply with all Part B requirements without exception.
Part C decision deadline: Approximately December 2026 — Commission must issue final determination. A Part A listing would prohibit all EGCG-containing food additions in the EU regardless of dose. EU importers must monitor this timeline: business continuity planning is required.
2. Part B vs. Part C: What Each Classification Means
| Classification | Legal Status | Current EGCG Products Affected | Commercial Impact |
|---|---|---|---|
| Part B — Restricted | Substance permitted ONLY under specified conditions. Violations = placing prohibited product on market (Article 12, EC 1925/2006) | All GTE products containing EGCG at any dose — label requirements apply even to low-dose products | Mandatory reformulation if ≥800 mg EGCG/day; mandatory label changes for ALL EGCG products regardless of dose |
| Part C — Under Scrutiny | Under scientific review; products may remain on market subject to monitoring; Commission decision pending within 4 years of entry into force | All GTE containing EGCG at any dosage including products already compliant with Part B | Supply chain risk — Part C may become Part A by December 2026; brands must monitor EFSA review and Commission determination |
| Part A — Prohibited (possible future) | Addition to food prohibited without exception | Not current status for EGCG — worst-case December 2026 outcome | Complete market withdrawal if reached |
Table 1 — Annex III Classification: Legal Consequences for EU EGCG Products
3. The Four Mandatory Warning Texts — Verbatim, Legally Required
The following warning texts are the exact statements mandated by the "Additional Requirements" column of the Part B table in Annex III as inserted by Article 1 of Regulation (EU) 2022/2340. These texts are legally required verbatim. Paraphrasing or abbreviation constitutes labeling non-compliance.
Warning 1 (other green tea products):
"Should not be consumed if you are consuming other products containing green tea on the same day."
Warning 2 (vulnerable populations):
"Should not be consumed by pregnant or lactating women and children below 18 years old."
Warning 3 (empty stomach):
"Should not be consumed on an empty stomach."
Additional mandatory content declaration (not a warning — required label information):
The label shall provide the maximum number of portions of the food for daily consumption and a warning not to consume a daily amount of 800 mg of (−)-epigallocatechin-3-gallate or more.
The label shall indicate the content of (−)-epigallocatechin-3-gallate per portion of the food.
EU food labeling rules (Regulation (EU) No 1169/2011) require mandatory label information in a language easily understood by consumers in each member state of sale. A product sold in Germany must carry warnings in German; France in French; multi-market products need multi-language formats. Always use the official EUR-Lex translation from OJ publication of Regulation (EU) 2022/2340 (CELEX:32022R2340) as the authoritative source — not secondary regulatory summaries. Errors in translated warnings constitute labeling non-compliance.
4. Technical Parameter Table: Daily Limits, Label Requirements, and Regulatory Scope
| Requirement | Regulatory Text | Applies To | Compliant? | Action Required |
|---|---|---|---|---|
| Maximum EGCG per daily portion | <800 mg EGCG from green tea extracts per daily portion | All food supplements and fortified foods containing GTE with EGCG sold in EU | OK if daily dose <800 mg EGCG | Reformulate or reduce dose if any single-day consumption scenario delivers ≥800 mg EGCG; calculate for maximum recommended daily consumption |
| EGCG content declared per portion | Label must indicate EGCG mg per portion of food | All products — including low-dose | Non-compliant if label shows only "green tea extract Xmg" without EGCG mg | Calculate and declare EGCG mg per serving; requires supplier-confirmed batch EGCG% to back-calculate |
| Max portions per day stated | Label must state maximum number of portions per day | All products | Non-compliant if absent | Add "Maximum X portions per day"; verify X portions × EGCG per portion <800 mg |
| 800 mg daily cap warning | Warning not to consume 800 mg EGCG or more per day | All products | Non-compliant if absent — even on low-dose products | Add explicit 800 mg daily cap warning regardless of actual EGCG dose |
| Warning 1: Other green tea | "Should not be consumed if you are consuming other products containing green tea on the same day." | All products | Non-compliant if absent or paraphrased | Add verbatim text |
| Warning 2: Vulnerable populations | "Should not be consumed by pregnant or lactating women and children below 18 years old." | All products | Non-compliant if age threshold differs (e.g., "under 16") | Exact text mandatory; "below 18 years old" is legally specified |
| Warning 3: Empty stomach | "Should not be consumed on an empty stomach." | All products | Non-compliant if absent | Add verbatim text |
| Exempt products | Traditional brewed green tea infusions; RTD drinks with ≥120 mg dry extract/100 mL equivalent to traditional tea; EGCG ≥90% novel food (EU 2017/2470) | Traditional tea; EGCG ≥90% specifically | Exempt — different regulatory pathway | Novel food exemption requires ≥90% EGCG purity and compliance with EU 2017/2470 conditions of use |
Table 2 — EU Regulation 2022/2340: Complete Label Requirement Matrix
5. Serving Size Calculation: Staying Below 800 mg with Batch Variance Safety Margin
The 800 mg/day limit is more complex than it appears. It must account for: (a) declared EGCG per serving; (b) batch-to-batch variance in the supplier's EGCG assay results; (c) label rounding; (d) consumer multi-serving scenarios. A brand formulating at exactly 790 mg EGCG/day using mean batch assay — with a supplier whose EGCG content varies ±8% between batches — will periodically produce batches delivering up to 853 mg EGCG/day, breaching the regulatory limit despite apparent label compliance.
Formula: EGCG per day (mg) = W_ingredient (mg) × (EGCG% / 100) × n
Where W_ingredient = weight of GTE ingredient per serving (mg); EGCG% = batch-specific HPLC result (% w/w); n = maximum servings per day.
Example: Capsule contains 500 mg GTE (50% EGCG grade). Batch EGCG% = 51.3%. Recommended 3 capsules/day.
EGCG per day = 500 × 0.513 × 3 = 769.5 mg — compliant.
If next batch EGCG% = 55.2%: EGCG per day = 500 × 0.552 × 3 = 828 mg — NON-COMPLIANT.
This demonstrates why batch-specific EGCG assay is mandatory — not just the nominal grade specification.
Formula: W_max (mg per serving) = 799 / (EGCG%_max / 100) / n
Where EGCG%_max = nominal assay + maximum batch variance; n = max servings/day; 799 = 800 mg with 1 mg safety buffer.
Example: 50% EGCG grade; supplier batch variance ±5% (so EGCG%_max = 52.5%); 3 servings/day.
W_max = 799 / (52.5/100) / 3 = 507.3 mg GTE per serving
Apply 5% additional safety factor: W_design = 507 × 0.95 = 482 mg per serving — provides buffer against method variation at buyer's own QC testing.
| Scenario | GTE Grade | GTE/Serving (mg) | Servings/Day | Batch EGCG% (worst case) | EGCG/Day (mg) | Compliant? |
|---|---|---|---|---|---|---|
| A — Conservative, high-variance supplier | 50% EGCG | 400 | 3 | 58% (+16%) | 696 | Yes |
| B — At-limit, high-variance supplier | 50% EGCG | 500 | 3 | 58% (+16%) | 870 | NO — breach |
| C — At-limit, low-variance supplier (±5%) | 50% EGCG | 500 | 3 | 52.5% (+5%) | 787 | Yes |
| D — EGCG 98%, standard dose | 98% EGCG | 250 | 3 | 99% (+1%) | 742 | Yes |
| E — EGCG 98%, high dose | 98% EGCG | 300 | 3 | 99% | 891 | NO — breach |
| F — EGCG 98%, safety-buffered design | 98% EGCG | 265 | 3 | 99% | 787 | Yes — 13 mg buffer |
Table 3 — EGCG Daily Dose Scenarios: Impact of Batch Variance on Regulatory Compliance
Warning 1 exists because consumers may combine EGCG supplements with other green tea products. The 800 mg/day limit applies to cumulative daily EGCG from all sources. A product designed at 750 mg EGCG/day leaves only 50 mg headroom — virtually zero for a consumer also drinking a green tea supplement beverage. Industry best practice for EU compliance: design single-product EGCG dose at no more than 600–650 mg/day, leaving ≥150 mg headroom for co-consumption scenarios.
6. EFSA Science Behind the Limit: Hepatotoxicity and the 800 mg Basis
1. No safe intake level identified: EFSA could not identify a daily intake of green tea catechins from extracts that does not give rise to concerns about harmful effects to health for the general population. This extraordinary negative finding drove the dual Part B/Part C listing rather than a simple UL-based restriction.
2. Hepatotoxicity at ≥800 mg/day: Clinical interventional trials showed intake of doses equal to or above 800 mg EGCG/day in food supplement form induced a statistically significant increase of serum transaminases (ALT, AST) in treated subjects vs. controls — indicative of hepatocellular injury. Below 800 mg/day, hepatotoxicity evidence from controlled trials was not observed — but EFSA noted absence of evidence ≠ evidence of absence.
3. Idiosyncratic hepatotoxicity at any dose: Rare cases of serious liver injury (including liver failure requiring transplantation) documented following GTE supplementation below 800 mg EGCG/day. EFSA concluded these are probably due to idiosyncratic reactions — individual susceptibility not predictable from dose. This underlies the Part C listing: even at doses below the Part B limit, a small subset may experience severe liver injury regardless of dose.
4. Fasted vs. fed state: EGCG bioavailability and hepatic exposure are higher under fasted conditions — driving the empty stomach warning. Consuming EGCG with food substantially reduces peak hepatic EGCG concentrations.
Serum transaminase elevation: ALT and AST are liver enzymes released into the bloodstream when hepatocytes are injured. EGCG-induced increase in ALT/AST at ≥800 mg/day in clinical trials was statistically significant — indicating subclinical hepatic stress even without symptomatic liver disease. This does not mean every consumer at 800 mg/day experiences measurable injury — the population mean of these markers rose significantly.
Implication for product claims: EU-market EGCG products should not carry claims implying liver support or hepatoprotective effects — inconsistent with the regulatory basis for EGCG restriction. EFSA has not authorized any health claims for EGCG or green tea extract under Regulation (EC) 1924/2006.
Finished product QC: For EU-market products, implement batch release protocol including independent EGCG assay on each finished product batch — not just incoming raw material testing. The finished product EGCG per serving is the legally relevant number.
7. The Novel Food Exception: EGCG ≥90% Under Regulation 2017/2470
Regulation (EU) 2022/2340 Recital 17 explicitly states: "This Regulation should not affect the use in fortified foods and food supplements of (−)-epigallocatechin-3-gallate as a highly purified extract from the leaves of green tea (Camellia sinensis (L.) Kuntze) containing a minimum of 90% (−)-epigallocatechin-3-gallate. That substance is safe and authorised for use as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and is subject to the conditions of use and specifications laid down by Commission Implementing Regulation (EU) 2017/2470." The practical implication: EGCG 98% (≥90% EGCG) operates under a separate regulatory pathway — it has been specifically safety-assessed by EFSA as a novel food with defined conditions of use. This exemption applies only to the specific highly purified EGCG novel food ingredient — not to GTE of lower purity sold in the same formulation.
| Product Type | Regulatory Pathway | 800 mg Limit? | Mandatory Warnings? | Notes |
|---|---|---|---|---|
| GTE containing EGCG, purity below 90% (e.g., GTE 50% catechins, GTE 40% EGCG) | EC 1925/2006 Annex III Part B + C as amended by EU 2022/2340 | Yes | Yes — all four warnings | Most commercial GTE grades fall here; EGCG per serving must be batch-calculated from supplier HPLC COA |
| EGCG ≥90% highly purified novel food (e.g., EGCG 90%, 95%, 98%) | EU 2015/2283 Novel Food + Commission Implementing Regulation (EU) 2017/2470 | No — exempt from EU 2022/2340 Part B | Not mandated by EU 2022/2340; novel food authorization may have own conditions | Requires sourcing EGCG ≥90% specifically authorized as novel food; purity must be batch-verified by HPLC |
| Traditional green tea infusion | General food law — not subject to Annex III restriction | No — explicitly excluded | No | EFSA confirmed traditional infusion "generally considered safe" |
Table 4 — Regulatory Pathway by EGCG Product Type: Applicability of EU 2022/2340
8. Supplier Audit Checklist: Batch Consistency and Dossier Requirements
A 50% EGCG grade supplier with ±15% batch variance (EGCG% ranging 42.5%–57.5%) introduces a ±15 percentage-point uncertainty into your daily EGCG calculation. At 500 mg GTE × 3 servings/day: worst-case EGCG = 500 × 0.575 × 3 = 862.5 mg — above the regulatory limit. The label shows "EGCG 225 mg/serving" (mean 50% grade) but actual batches deliver up to 287 mg. This is not theoretical — it is endemic with commodity botanical extracts without batch-specific HPLC documentation. The practical EU standard: supplier batch-to-batch RSD ≤5% for EGCG% across minimum 10 consecutive production batches.
Required Documentation — EU Compliance Dossier
- Batch-specific HPLC EGCG assay per shipment: EGCG result in % w/w; USP <621> reversed-phase HPLC; Rs between EGCG and GCG peaks ≥2.0; reference standard identity and purity (USP-1236700 or equivalent); LOQ ≤0.1%; result linked to specific production lot; test date within 3 months of shipment.
- Full individual catechin profile per batch: EGCG, ECG, EGC, EC, GCG, GC individually quantified in % w/w; total catechins sum; EGCG as % of total catechins. Enables independent verification that catechin profile is consistent with declared EGCG assay.
- 10-batch historical EGCG variance data: Table of EGCG% results for 10 most recent consecutive batches; calculated RSD; supplier commitment that RSD ≤5% is a specification requirement; OOS investigation records for any batch deviating >5% from nominal.
- COA declaring EGCG mg/kg: In addition to EGCG% result, COA should state EGCG content in mg/kg (e.g., "EGCG: 50.3% w/w = 503,000 mg/kg"). This format enables EU importers to calculate EGCG mg per serving directly. This is the format required by most EU regulatory affairs teams for dossier preparation.
- Analytical method validation report (ICH Q2(R1)): Linearity (R² ≥0.9990); precision (RSD ≤2% intraday, ≤3% interday); accuracy (recovery 98–102%); specificity (Rs EGCG/GCG ≥2.0). Provided once during supplier qualification; updated when method is changed.
- GMP/quality system certification: ISO 22000, FSSC 22000, or equivalent; cGMP compliance documentation; EU importers are legal entities responsible for ensuring ingredients comply with EU food law.
- Heavy metals by ICP-MS (batch-specific): Pb, Cd, As, Hg per batch; ISO 17025 accredited laboratory preferred.
- Signed Quality Agreement: EGCG% specification range including upper and lower limits; batch release criteria; COA format and required fields; change notification; right-to-audit; corrective action procedure for OOS results.
- Regulatory compliance statement for EU 2022/2340: Written supplier declaration confirming awareness and compliance with EU 2022/2340; statement confirming product is green tea extract containing EGCG (not the ≥90% novel food grade) and is manufactured per conditions applicable to Part B Annex III; OR for EGCG ≥90%, a declaration of novel food authorization reference.
Supplier Disqualification Triggers
- Cannot provide batch-specific HPLC EGCG assay — offers only "typical" or "nominal" values without lot-specific documentation
- Historical batch variance shows RSD >10% for EGCG% across recent batches — unacceptable for EU-compliant formulation
- COA does not state individual catechin profile — only "total catechins" or "total polyphenols" without EGCG-specific result
- No analytical method validation data for HPLC assay
- Unaware of EU Regulation 2022/2340 — cannot provide regulatory compliance statement
- No Quality Agreement offered or refuses to sign buyer's Quality Agreement
- GMP certification expired, covers different facility, or does not cover the EGCG production process
9. Blue Eyes Biotech Solution: EU-Compliant EGCG 98% with Standardized Regulatory Dossiers
Globally Compliant EGCG 98% — Built for EU Regulatory Affairs Teams
Blue Eyes Biotech's EGCG 98% is supplied with a standardized compliance dossier designed to meet the documentation requirements of EU regulatory affairs teams, UK FSA notifications, and US supplement quality agreements simultaneously. The dossier is a technical compliance package mapped to the specific verification steps that EU importers must complete before placing EGCG-containing products on the EU market.
Why most Chinese EGCG suppliers fail EU buyers: EU compliance for EGCG is not a one-time documentation exercise — it is a per-batch obligation. Every production lot requires a batch-specific HPLC EGCG assay with full catechin profile, linked to a specific COA and lot number, in a format that allows the EU importer to calculate EGCG mg per serving and verify the daily dose limit before release. Most commodity suppliers issue a single "typical" COA for a grade specification and cannot generate batch-specific EGCG documentation in the required format.
Blue Eyes Biotech Standard EU Compliance Package (per shipment batch):
- EGCG assay: ≥98.0% (batch-specific HPLC; USP <621>; Rs EGCG/GCG ≥2.0; USP-1236700 reference standard; R² ≥0.9991; recovery 99.1–100.4%)
- Catechin profile: Full individual EGCG, ECG, EGC, EC, GCG, GC quantification per batch; EGCG mg/kg stated on COA
- Batch variance commitment: Batch-to-batch RSD ≤5% for EGCG% across all production batches; historical 10-batch variance table available on request
- Heavy metals (ICP-MS, batch-specific): Pb ≤0.5 ppm; Cd ≤0.1 ppm; As ≤0.2 ppm; Hg ≤0.1 ppm
- Residual solvents (USP <467>): Class 1 ND; Class 3 ethanol ≤500 ppm; full panel on qualification batch
- Regulatory compliance statement: Written declaration referencing EU Regulation 2022/2340 and, for EGCG ≥90%, the novel food authorization pathway under EU 2017/2470
- Quality Agreement: Standard template available; customization to buyer's QA framework supported; includes EGCG% upper/lower specification limits, batch release criteria, change notification, right-to-audit clause
- Serving size calculation support: Technical support for EU serving size calculation (Methods 1 and 2 above) using buyer's formulation parameters and our batch EGCG data; available pre-launch and on each new batch receipt
EGCG 98% as the novel food pathway: At ≥98% EGCG purity, our EGCG 98% qualifies for the novel food exemption from EU Regulation 2022/2340 under Regulation (EU) 2017/2470. EU importers may use this pathway to avoid mandatory warning label requirements and the 800 mg/day restriction — subject to compliance with the novel food conditions of use for the specific food category.
Request Our EU Compliance Dossier + Free 20g Sample
Receive batch-specific EGCG 98% COA with full catechin profile, 10-batch variance table, regulatory compliance statement for EU 2022/2340, and Quality Agreement template — alongside a free 20g analytical sample for your own HPLC verification.
For Direct Regulatory Affairs Inquiries & EU Dossier Support
Our EU compliance team assists with serving size calculations, label claim verification, and Quality Agreement drafting for EU market entry.
Email: [email protected]
10. FAQ
Yes — and you need to determine and declare the EGCG content per serving. "95% polyphenols" ≠ "95% EGCG" — the EGCG fraction of a 95% polyphenol GTE is typically 40–65% of extract weight, not 95%. At 250 mg extract × 2 capsules = 500 mg extract/day: if batch EGCG% = 50%, daily EGCG = 250 mg — well below 800 mg limit. But you must still: (1) conduct HPLC batch testing to confirm actual EGCG%; (2) declare EGCG mg per serving on label; (3) include all four mandatory warning statements; (4) state maximum 2 capsules per day with the 800 mg daily cap warning. The Part B requirements apply at any EGCG dose — not only above 800 mg. The limit triggers prohibition; the label requirements apply to all products.
Potentially yes — but the exemption is conditional. Regulation (EU) 2022/2340 Recital 17 exempts "highly purified extract containing a minimum of 90% (−)-epigallocatechin-3-gallate" when used as a novel food authorized under Regulation (EU) 2015/2283 per the conditions in Commission Implementing Regulation (EU) 2017/2470. To claim this exemption: (a) confirm your EGCG contains ≥90% EGCG by batch-specific HPLC; (b) confirm the product category is covered by EU 2017/2470 authorization conditions; (c) confirm maximum use levels in EU 2017/2470 for your food category are met. If your EGCG is sourced as a standard ingredient without formal novel food authorization reference, the exemption claim is legally uncertain. Consult EU regulatory affairs counsel before relying on this exemption for product launch.
A product delivering ≥800 mg EGCG/day is a non-compliant product under Part B — equivalent to a prohibited product. (a) Discovered at incoming QC before manufacture: Reject batch; invoke Quality Agreement OOS clause; no product recall required. (b) Discovered after manufacture, before release: Quarantine batch; assess whether exceedance is systematic; if batch delivers ≥800 mg EGCG/day, it cannot be released to EU market; arrange destruction or rework. (c) Discovered after EU market placement: Trigger product recall under EU market surveillance; notify national competent authority; notify EU RASFF if food safety risk present. This is why batch-specific HPLC verification by the EU importer (not relying solely on supplier COA) before release is essential risk management.
Legally yes — Part B states "less than 800 mg" per daily portion. However, 799 mg provides essentially zero practical compliance margin: (a) HPLC analytical uncertainty ±1–2% = ±8–16 mg at 799 mg; (b) batch-to-batch supplier variance could shift the dose over 800 mg; (c) a consumer taking one extra capsule. For robust EU compliance, design daily EGCG dose at ≤700 mg from the worst-case batch calculation — this provides meaningful buffer against all sources of variance.
Part C is the EU's regulatory holding area — evidence sufficient for concern but insufficient for immediate prohibition. The Commission must decide by approximately December 2026. Three possible outcomes: (1) Escalation to Part A (full prohibition): All EGCG food additions prohibited in EU regardless of dose — would eliminate the EU EGCG supplement market. (2) Maintained in Part B with modified conditions: Limit may be reduced (e.g., to 400–600 mg) or additional restrictions added. (3) Removal with establishment of safe upper level: Possible if new submitted safety data convinces EFSA. For long-term strategy: monitor EFSA and Commission procedures closely; consider dual-format product development (traditional green tea infusion format as regulatory hedge); ensure your supplier can provide safety substantiation data submittable to EFSA under Article 8(4) if commercially warranted.
Related Blue Eyes Biotech Knowledge Center Articles
- Navigating EU Regulation 2022/2340: Full Overview
- EGCG 98% Technical Data Sheet — Full Specification and Test Methods
- HPLC vs. UV-Vis for EGCG: How False Purity Readings Are Generated
- How to Read and Verify a Nutraceutical Ingredient COA
- EGCG Pesticide Compliance: EU Regulation 396/2005 MRL Guide
- EGCG Green Tea Extract: Complete B2B Sourcing and Buyer Guide
